StreetInsider.com News Articles

Form 4 Annexon, Inc. For: May 28 Filed by: Satter Muneer A

Fri, 29 May 2026 17:21:00 -0400

si-local-file:///var/storage/secattach/20260529/26576626.html

Form 4 Annexon, Inc. For: May 28 Filed by: Satter Muneer A

Fri, 29 May 2026 17:21:00 -0400

si-local-file:///var/storage/secattach/20260529/26576626.html

Annexon to Participate in Upcoming June Investor Conferences

Wed, 27 May 2026 08:00:00 -0400

BRISBANE, Calif., May 27, 2026 (GLOBE NEWSWIRE) -- Annexon, Inc. (Nasdaq: ANNX), a biopharmaceutical company advancing the next generation platform of targeted immunotherapies aimed at neuroinflammatory diseases that impact nearly 10 million people worldwide, today announced that Douglas Love, Esq., president & chief executive officer, will participate in fireside chats during the following June investor conferences:

Jefferies Global Healthcare Conference on Wednesday, June 3, 2026, at 11:40 a.m. ET in New York, NY; and,
Goldman Sachs 47th Annual Global Healthcare Conference on Tuesday, June 9, 2026, at 8:00 a.m. ET

Annexon to Participate in Upcoming June Investor Conferences

Wed, 27 May 2026 08:00:00 -0400

Jefferies Global Healthcare Conference on Wednesday, June 3, 2026, at 11:40 a.m. ET in New York, NY; and,
Goldman Sachs 47th Annual Global Healthcare Conference on Tuesday, June 9, 2026, at 8:00 a.m. ET

Annexon to Participate in Upcoming June Investor Conferences

Wed, 27 May 2026 08:00:00 -0400

Jefferies Global Healthcare Conference on Wednesday, June 3, 2026, at 11:40 a.m. ET in New York, NY; and,
Goldman Sachs 47th Annual Global Healthcare Conference on Tuesday, June 9, 2026, at 8:00 a.m. ET

Annexon to Participate in Upcoming June Investor Conferences

Wed, 27 May 2026 08:00:00 -0400

Jefferies Global Healthcare Conference on Wednesday, June 3, 2026, at 11:40 a.m. ET in New York, NY; and,
Goldman Sachs 47th Annual Global Healthcare Conference on Tuesday, June 9, 2026, at 8:00 a.m. ET

Annexon to Participate in Upcoming June Investor Conferences

Wed, 27 May 2026 08:00:00 -0400

Jefferies Global Healthcare Conference on Wednesday, June 3, 2026, at 11:40 a.m. ET in New York, NY; and,
Goldman Sachs 47th Annual Global Healthcare Conference on Tuesday, June 9, 2026, at 8:00 a.m. ET

Annexon to Participate in Upcoming June Investor Conferences

Wed, 27 May 2026 08:00:00 -0400

Jefferies Global Healthcare Conference on Wednesday, June 3, 2026, at 11:40 a.m. ET in New York, NY; and,
Goldman Sachs 47th Annual Global Healthcare Conference on Tuesday, June 9, 2026, at 8:00 a.m. ET

Annexon to Participate in Upcoming June Investor Conferences

Wed, 27 May 2026 08:00:00 -0400

Jefferies Global Healthcare Conference on Wednesday, June 3, 2026, at 11:40 a.m. ET in New York, NY; and,
Goldman Sachs 47th Annual Global Healthcare Conference on Tuesday, June 9, 2026, at 8:00 a.m. ET

Annexon to Participate in Upcoming June Investor Conferences

Wed, 27 May 2026 08:00:00 -0400

Jefferies Global Healthcare Conference on Wednesday, June 3, 2026, at 11:40 a.m. ET in New York, NY; and,
Goldman Sachs 47th Annual Global Healthcare Conference on Tuesday, June 9, 2026, at 8:00 a.m. ET

Annexon Reports Inducement Grants to New Employees Under Nasdaq Listing Rule 5635(c)(4)

Mon, 18 May 2026 16:05:00 -0400

BRISBANE, Calif., May 18, 2026 (GLOBE NEWSWIRE) -- Annexon, Inc. (Nasdaq: ANNX), a biopharmaceutical company advancing the next generation platform of targeted immunotherapies aimed at neuroinflammatory diseases that impact nearly 10 million people worldwide, today announced that it has granted inducement to three new non-executive employees under the terms of the 2022 Employment Inducement Award Plan. The equity awards were approved on May 11, 2026, in accordance with Nasdaq Listing Rule 5635(c)(4).

In the aggregate, the new non-executive employees received options to purchase 243,000 shares of Annexon common stock. The options carry a ten-year term

Annexon Reports Inducement Grants to New Employees Under Nasdaq Listing Rule 5635(c)(4)

Mon, 18 May 2026 16:05:00 -0400

In the aggregate, the new non-executive employees received options to purchase 243,000 shares of Annexon common stock. The options carry a ten-year term

Annexon Reports Inducement Grants to New Employees Under Nasdaq Listing Rule 5635(c)(4)

Mon, 18 May 2026 16:05:00 -0400

In the aggregate, the new non-executive employees received options to purchase 243,000 shares of Annexon common stock. The options carry a ten-year term

Annexon Reports Inducement Grants to New Employees Under Nasdaq Listing Rule 5635(c)(4)

Mon, 18 May 2026 16:05:00 -0400

In the aggregate, the new non-executive employees received options to purchase 243,000 shares of Annexon common stock. The options carry a ten-year term

Form SCHEDULE 13G/A Annexon, Inc. Filed by: BIOTECHNOLOGY VALUE FUND L P

Fri, 15 May 2026 16:06:00 -0400

si-local-file:///var/storage/secattach/20260515/26504925.html

Form SCHEDULE 13G/A Annexon, Inc. Filed by: BIOTECHNOLOGY VALUE FUND L P

Fri, 15 May 2026 16:06:00 -0400

si-local-file:///var/storage/secattach/20260515/26504925.html

Form 4 Annexon, Inc. For: May 11 Filed by: Carson William H.

Wed, 13 May 2026 16:30:00 -0400

si-local-file:///var/storage/secattach/20260513/26486712.html

Form 4 Annexon, Inc. For: May 11 Filed by: Carson William H.

Wed, 13 May 2026 16:30:00 -0400

si-local-file:///var/storage/secattach/20260513/26486712.html

Goldman Sachs Starts Annexon Biosciences (ANNX) at Neutral

Tue, 12 May 2026 05:15:03 -0400

Goldman Sachs analyst Salveen Richter initiates coverage on Annexon Biosciences (NASDAQ: ANNX) with a Neutral rating and a price target of $7.00.

The analyst comments "We initiate coverage on Annexon Biosciences (ANNX) at Neutral, with a 12-month price target of $7. ANNX is a clinical-stage biotechnology company developing therapeutics for neuroinflammatory diseases via inhibition of the complement pathway, a component of the immune system. We view the Ph3 data for vonaprument, an intravitreal anti-C1q, in geographic atrophy (GA) in 4Q as a binary event, with a focus on vision preservation on the primary endpoint of best corrected visual acuity (BCVA) to

Goldman Sachs Starts Annexon Biosciences (ANNX) at Neutral

Tue, 12 May 2026 05:15:03 -0400

Goldman Sachs analyst Salveen Richter initiates coverage on Annexon Biosciences (NASDAQ: ANNX) with a Neutral rating and a price target of $7.00.

110 Years. 110 Stories. 110 Reasons to Raise Awareness for GBS

Mon, 11 May 2026 10:00:00 -0400

CONSHOHOCKEN, Pa., May 11, 2026 (GLOBE NEWSWIRE) -- May is GBS|CIDP Awareness Month and this year marks 110 years since the discovery of Guillain-Barré syndrome (GBS), which was first identified and named in 1916 by French neurologists Georges Guillain, Jean Alexandre Barré, and André Strohl. Distinguished as a unique condition, this landmark identification occurred 110 years ago, marking over a century of research into the disorder. Yet even today, with so many international GBS patient registries and research efforts, there are still thousands who face the devastating challenges of this condition every year. 110 years later, and there is

110 Years. 110 Stories. 110 Reasons to Raise Awareness for GBS

Mon, 11 May 2026 10:00:00 -0400

CONSHOHOCKEN, Pa., May 11, 2026 (GLOBE NEWSWIRE) -- May is GBS|CIDP Awareness Month and this year marks 110 years since the discovery of Guillain-Barré syndrome (GBS), which was first identified and named in 1916 by French neurologists Georges Guillain, Jean Alexandre Barré, and André Strohl. Distinguished as a unique condition, this landmark identification occurred 110 years ago, marking over a century of research into the disorder. Yet even today, with so many international GBS patient registries and research efforts, there are still thousands who face the devastating challenges of this condition every year. 110 years later, and there is

110 Years. 110 Stories. 110 Reasons to Raise Awareness for GBS

Mon, 11 May 2026 10:00:00 -0400

CONSHOHOCKEN, Pa., May 11, 2026 (GLOBE NEWSWIRE) -- May is GBS|CIDP Awareness Month and this year marks 110 years since the discovery of Guillain-Barré syndrome (GBS), which was first identified and named in 1916 by French neurologists Georges Guillain, Jean Alexandre Barré, and André Strohl. Distinguished as a unique condition, this landmark identification occurred 110 years ago, marking over a century of research into the disorder. Yet even today, with so many international GBS patient registries and research efforts, there are still thousands who face the devastating challenges of this condition every year. 110 years later, and there is

110 Years. 110 Stories. 110 Reasons to Raise Awareness for GBS

Mon, 11 May 2026 10:00:00 -0400

CONSHOHOCKEN, Pa., May 11, 2026 (GLOBE NEWSWIRE) -- May is GBS|CIDP Awareness Month and this year marks 110 years since the discovery of Guillain-Barré syndrome (GBS), which was first identified and named in 1916 by French neurologists Georges Guillain, Jean Alexandre Barré, and André Strohl. Distinguished as a unique condition, this landmark identification occurred 110 years ago, marking over a century of research into the disorder. Yet even today, with so many international GBS patient registries and research efforts, there are still thousands who face the devastating challenges of this condition every year. 110 years later, and there is

110 Years. 110 Stories. 110 Reasons to Raise Awareness for GBS

Mon, 11 May 2026 10:00:00 -0400

CONSHOHOCKEN, Pa., May 11, 2026 (GLOBE NEWSWIRE) -- May is GBS|CIDP Awareness Month and this year marks 110 years since the discovery of Guillain-Barré syndrome (GBS), which was first identified and named in 1916 by French neurologists Georges Guillain, Jean Alexandre Barré, and André Strohl. Distinguished as a unique condition, this landmark identification occurred 110 years ago, marking over a century of research into the disorder. Yet even today, with so many international GBS patient registries and research efforts, there are still thousands who face the devastating challenges of this condition every year. 110 years later, and there is